| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
RCT of SSRI and mirtazapine including 150 depressive patients for 12 weeks resulted that mirtazapine showed faster remission than SSRIs. In non-responder at week 4, no difference was seen between the monotherapy and the combination group. We confirmed that EPI confers a large contribution to the treatment response at week 6 to paroxetine and milnacipran and less to fluvoxamine and genetic variants in ADRA2A and HTRA1A also influenced milnacipran response and 5-HTTLPR and FGF2 influenced fluvoxamine response in the multiple linear regression analysis. A genome-wide association study was performed using data from 865 subjects of ISPC. Top association results in the meta-analysis of response included SNPs in the HPRTP4 /VSTM5 region, which approached genome-wide significance and SNPs in NRG1. A pathway analysis identified the SNPs on JUN, CREB1 and RELA genes within the regulatory region nucleic acid binding pathway as an possible predictors of SSRI response.
|
